Glenmark Pharmaceuticals and Canada-based SaNOtize Research & Development have introduced the Nitric Oxide Nasal Spray (NONS) to treat Covid-19 in adult patients in India.
To be marketed under the brand name FabiSpray, the treatment is intended for Covid-19 patients at increased disease progression risk.
The latest development comes after Glenmark obtained manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS under the accelerated approval process.
FabiSpray has been designed to destroy the SARS-CoV-2 virus that causes Covid-19 in the upper airways.
Furthermore, the spray has established anti-microbial properties with a direct virucidal effect on the virus.
A great company to deal with, extremely reliable with a good range of products. Excellent product knowledge, great communication & customer service, fair prices and fast delivery.